# A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

> **NCT00044135** · PHASE2 · UNKNOWN · sponsor: **Triangle Pharmaceuticals** · enrollment: 30 (—)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** clevudine (drug)

## Key facts

- **NCT ID:** NCT00044135
- **Lead sponsor:** Triangle Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044135, "A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00044135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*